Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
International Journal of Cancer
|
September 16, 2015
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience
Carole Helissey, Pamela Biondani, Florian Roquet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2017
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
Eric Angevin, Philippe A Cassier, Antoine Italiano, et al.
Cancer Medicine
|
February 20, 2020
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Patricia Martin-Romano, Eduardo Castanon, Samy Ammari, et al.
Cancers
|
December 15, 2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, et al.
British Journal of Cancer
|
December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
Oncotarget
|
March 27, 2016
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
Eric Deutsch, Christine Haie-Meder, Mohamed Amine Bayar, et al.
Frontiers in Cardiovascular Medicine
|
October 24, 2022
Predictors and neurological consequences of periprocedural cerebrovascular events following transcatheter aortic valve implantation with self-expanding valves
Ferenc Imre Suhai, Andrea Varga, Bálint Szilveszter, et al.
Neuroradiology
|
August 1, 2022
Microstructural alterations measured by diffusion tensor imaging following transcatheter aortic valve replacement and their association with cerebral ischemic injury and cognitive function - a prospective study
Andrea Varga, Gyula Gyebnár, Ferenc Imre Suhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, et al.
European Heart Journal. Cardiovascular Imaging
|
August 7, 2020
Quantification of hypo-attenuated leaflet thickening after transcatheter aortic valve implantation: clinical relevance of hypo-attenuated leaflet thickening volume
Júlia Karády, Astrid Apor, Anikó I Nagy, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
International Journal of Cancer
|
September 16, 2015
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience
Carole Helissey, Pamela Biondani, Florian Roquet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2017
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study
Eric Angevin, Philippe A Cassier, Antoine Italiano, et al.
Cancer Medicine
|
February 20, 2020
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Patricia Martin-Romano, Eduardo Castanon, Samy Ammari, et al.
Cancers
|
December 15, 2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, et al.
British Journal of Cancer
|
December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
Oncotarget
|
March 27, 2016
Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients
Eric Deutsch, Christine Haie-Meder, Mohamed Amine Bayar, et al.
Frontiers in Cardiovascular Medicine
|
October 24, 2022
Predictors and neurological consequences of periprocedural cerebrovascular events following transcatheter aortic valve implantation with self-expanding valves
Ferenc Imre Suhai, Andrea Varga, Bálint Szilveszter, et al.
Neuroradiology
|
August 1, 2022
Microstructural alterations measured by diffusion tensor imaging following transcatheter aortic valve replacement and their association with cerebral ischemic injury and cognitive function - a prospective study
Andrea Varga, Gyula Gyebnár, Ferenc Imre Suhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, et al.
European Heart Journal. Cardiovascular Imaging
|
August 7, 2020
Quantification of hypo-attenuated leaflet thickening after transcatheter aortic valve implantation: clinical relevance of hypo-attenuated leaflet thickening volume
Júlia Karády, Astrid Apor, Anikó I Nagy, et al.
Page
of 11